12 Biomarkers to Monitor on GLP-1 Therapy
Whether you're on Ozempic, Wegovy, Mounjaro, or Zepbound — these are the markers that tell you whether your therapy is working, safe, and optimized. From standard blood work to next-generation mRNA profiling.
Metabolic Markers
These biomarkers track how your body processes sugar, fat, and insulin — the core systems GLP-1 medications target.
Fasting Glucose
Normal: 70–99 mg/dL
What it measures: Blood sugar levels after an overnight fast.
Why it matters: GLP-1s improve insulin sensitivity and lower fasting glucose.
Tracking this shows whether your medication is reducing insulin resistance and improving
how efficiently your body uses sugar for energy.
HbA1c
Normal: <5.7%
What it measures: Average blood sugar over the past 2–3 months.
Why it matters: The gold standard for long-term glycemic control. A dropping
HbA1c confirms your GLP-1 therapy is producing sustained metabolic improvements — not just
day-to-day fluctuations.
Fasting Insulin
Normal: 2.6–24.9 µIU/mL
What it measures: Insulin levels after fasting — a direct measure of insulin resistance.
Why it matters: Falling fasting insulin means your body needs less insulin
to control blood sugar. GLP-1s should steadily improve this — if insulin stays high, your
therapy may need adjustment.
HOMA-IR
Optimal: <1.0 | Normal: <2.0
What it measures: Calculated insulin resistance index using fasting glucose and insulin.
Why it matters: HOMA-IR is arguably the single best snapshot of insulin
resistance. A declining score means your GLP-1 is doing its job at the metabolic level — even
before weight loss becomes visible.
Hepatic Markers
Your liver works harder during rapid metabolic change. These markers ensure it's handling the shift safely.
ALT (Alanine Aminotransferase)
Normal: 7–56 U/L
What it measures: An enzyme released when liver cells are damaged.
Why it matters: Rapid weight loss mobilizes fat stored in the liver. While GLP-1s
generally improve fatty liver disease, transient ALT spikes can signal the liver is under stress
during the transition. Monitoring catches this early.
AST (Aspartate Aminotransferase)
Normal: 10–40 U/L
What it measures: Another liver enzyme, also found in heart and muscle tissue.
Why it matters: Paired with ALT, the AST/ALT ratio helps distinguish between liver
stress and muscle-related enzyme release — particularly important since GLP-1 therapy can affect
lean muscle mass.
Lipid, Thyroid & Inflammatory Markers
Cardiovascular risk, thyroid safety, and systemic inflammation — the broader picture of how your body is responding.
Triglycerides
Normal: <150 mg/dL
What it measures: Fat circulating in your bloodstream.
Why it matters: Triglycerides are typically the first lipid marker to improve on
GLP-1 therapy — often dropping within 4–8 weeks. A declining triglyceride level is one of the earliest
traditional signs that your medication is working.
LDL Cholesterol
Optimal: <100 mg/dL
What it measures: "Bad" cholesterol that builds up in artery walls.
Why it matters: GLP-1s have demonstrated cardiovascular benefit in clinical trials.
Tracking LDL confirms whether the lipid-lowering effect is translating to reduced cardiovascular risk
for you specifically.
TSH (Thyroid-Stimulating Hormone)
Normal: 0.4–4.0 mIU/L
What it measures: How hard your thyroid is working.
Why it matters: GLP-1 medications carry an FDA boxed warning for medullary thyroid
carcinoma risk (observed in rodent studies). While human risk remains low, monitoring TSH
is standard clinical practice during GLP-1 therapy, especially for patients with thyroid history.
hs-CRP (High-Sensitivity C-Reactive Protein)
Low risk: <1.0 mg/L
What it measures: Systemic inflammation levels.
Why it matters: Chronic inflammation drives metabolic disease and cardiovascular risk.
GLP-1s have anti-inflammatory properties — a falling hs-CRP confirms these benefits are active.
Persistently elevated hs-CRP may signal that inflammation isn't responding to therapy.
mRNA Gene Expression Markers
This is where One Health Labs goes beyond standard blood work. While markers 1–10 show you what already happened, mRNA markers show you what's happening right now — at the molecular level.
Metabolic Pathway mRNA Panel
Leading Indicator
What it measures: Active gene expression across fat metabolism,
insulin signaling, and energy production pathways.
Why it matters: Your blood work might look unchanged at 4 weeks — but mRNA
can reveal whether lipogenesis (fat storage) genes are being suppressed, whether insulin receptor
signaling is improving, and whether mitochondrial biogenesis is ramping up. These molecular shifts
happen weeks before blood markers move.
Catabolic Gene Expression
Leading Indicator
What it measures: Muscle protein breakdown genes — specifically
MURF1 (TRIM63), MAFbx/Atrogin-1, and FOXO transcription factors.
Why it matters: One of the biggest concerns with GLP-1 therapy is losing
muscle along with fat. By the time you notice weakness or see it on a DEXA scan, significant
lean mass has already been lost. Catabolic mRNA markers detect muscle breakdown within 14 days —
early enough to intervene with exercise protocols or therapy adjustments.
Lagging vs. Leading Indicators
Markers 1–10 tell you what your body did over the past weeks and months. Markers 11–12 tell you what your body is doing right now.
| Standard Blood Work | mRNA Profiling | |
|---|---|---|
| Timing | Reflects past weeks/months | Reflects current molecular activity |
| Indicator Type | Lagging | Leading |
| Detects Response | After 8–12+ weeks | Within days to weeks |
| Muscle Loss | Visible on DEXA after months | Catabolic genes detectable in 14 days |
| Targets | ~10 individual analytes | Up to 48 gene targets per run |
Know Your Numbers.
Know Your Molecules.
Get the complete picture of your GLP-1 response — standard labs plus the mRNA layer that only One Health Labs provides.